Brief: Entrada Therapeutics Reports Positive Preliminary Data From Phase 1 Entr-601-44-101 Trial
24/06/2024 11:06
June 24 (Reuters) - Entrada Therapeutics Inc TRDA.O :
* ENTRADA THERAPEUTICS REPORTS POSITIVE PRELIMINARY DATA IN
HEALTHY VOLUNTEERS FROM PHASE 1 ENTR-601-44-101 TRIAL FOR
DUCHENNE MUSCULAR DYSTROPHY
Source text for Eikon: ID:nGNXNyv13
Further company coverage: TRDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entrada Therapeutics
See all newsBrief: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Entrada Therapeutics Q2 Collaboration Revenue USD 898 Thousand
Entrada Therapeutics Q2 net loss narrows on lower costs
Entrada Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview